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Systems-level  metabolic  network  reconstructions  and  the  derived  constraint-based  (CB)  mathematical
models  are  efﬁcient  tools  to explore  bacterial  metabolism.  Approximately  one-fourth  of  the  Mycobac-
terium  tuberculosis  (Mtb)  genome  contains  genes  that  encode  proteins  directly  involved  in its  metabolism.
These  represent  potential  drug  targets  that  can  be  systematically  probed  with  CB  models  through  the
prediction  of  genes  essential  (or  the  combination  thereof)  for the  pathogen  to  grow.  However,  gene
essentiality  depends  on the growth  conditions  and,  so  far, no  in  vitro  model  precisely  mimics  the  host
at  the different  stages  of mycobacterial  infection,  limiting  model  predictions.  These  limitations  can  be
circumvented  by combining  expression  data from  in  vivo samples  with a validated  CB  model,  creating
an  accurate  description  of  pathogen  metabolism  in the host.  To  this  end, we  present  here  a  thoroughly
13curated  and  extended  genome-scale  CB  metabolic  model  of Mtb quantitatively  validated  using C  mea-
surements.  We  describe  some  of  the efforts  made  in  integrating  CB  models  and  high-throughput  data  to
generate  condition  speciﬁc  models,  and  we  will  discuss  challenges  ahead.  This  knowledge  and  the  frame-
work  herein  presented  will  enable  to  identify  potential  new  drug  targets,  and will  foster  the  development
of  optimal  therapeutic  strategies.
© 2014  The  Authors.  Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).. The rise of multi-resistant Mycobacterium tuberculosis
nd the need for new intervention strategies
Mycobacterium tuberculosis (Mtb) is the etiological agent of
uberculosis (TB) and has re-emerged as a serious threat for human
ealth. In 2012, TB claimed the lives of 1.3 million people [1]. The
apid appearance of multi, extensively and totally drug-resistant
trains, emphasizes the adaptability of Mtb  and has raised concerns
f its impact to human health. Furthermore, due to the diverse
Abbreviations: CB, constraint-based; Mtb, Mycobacterium tuberculosis; TB,
uberculosis; gdw, grams of cell dry weight; BCG, Mycobacterium bovis Bacillus
almette-Guérin.
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ttp://dx.doi.org/10.1016/j.smim.2014.09.013
044-5323/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article ungenetic predisposition of the infected subjects, uncertainties on
long-term adverse effects and other safety concerns regarding the
rise of drug resistant strains, the development of new, effective and
affordable TB drugs has been slow [2]. New (combined) therapeu-
tic strategies are urgently required to combat these drug-resistant
strains [3].
In vitro studies have revealed sets of genes that are essential
for growth and survival under laboratory growth conditions [4,5].
Due to the differences between the in vivo and the in vitro environ-
ments this does not automatically imply that these sets of genes
are suitable drug targets. Besides, given all cellular components
from different types of networks, genes (and their products) that
may  be not essential on their own can be indispensable in combi-
nations not immediately obvious. A vital improvement would be
the expansion of these studies to in vivo or ex vivo models, such
as animal models, which would as faithfully as possible mimic
the onset and progression of the infection, as well as the strate-
gies against it [6]. An alternative and complementary method to
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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dentify suitable drug targets is to use mathematical descriptions
f the metabolism of Mtb  under in vivo conditions, circumvent-
ng experimental difﬁculties that arise with in vivo and ex vivo
tudies.
Approximately one-fourth of the annotated mycobacterial gene
ool encodes structural proteins known to be involved in its
etabolism presenting a wealth of enzymes and metabolites as
otential drug targets. Stoichiometric genome-scale models of
etabolism are essential to identify possible metabolic drug tar-
ets, as they provide a holistic view on metabolism. Drug targets
n the form of enzymes encoded by their speciﬁc genes, have been
dentiﬁed by gene essentiality predictions based on modeling the
n vivo environment [7]. Recent insights have clariﬁed the picture
f available metabolites to Mtb  inside the host and shed new light
n in vivo gene essentiality predictions [8–11].
Predictions on gene essentiality can be done using constraint-
ased (CB) metabolic models by simulating the effect of total loss
f an enzyme function in a metabolic network. This black and
hite scenario where a drug is able to completely shut down
n enzymatic reaction is not fully realistic. In most cases, drug
ffects are subtler, leading to only a partial loss of function [12].
urthermore, and owing to the network structures in which they
re embedded, genes may  code for proteins that are not essen-
ial per se,  but which do become so if equally non-essential
roteins to which they are connected become dysfunctional or
bsent. A reliable metabolic network topology, knowledge of
he available metabolites in the host, in vivo growth and sur-
ival requirements and strategies, and reliable and quantitative
redictions of metabolic activity are important and thus far
verlooked.
A stoichiometric genome-scale CB metabolic model that is
xperimentally validated, not only qualitatively for the correct
etwork topology, but also quantitatively for predicting ﬂuxes, pro-
ides many opportunities to further identify metabolic bottlenecks
nd weak spots. Instead of using only qualitative, topology based,
ethods such models can be explored for new drug targets and
ovel synergistic drug combinations using more realistic quantita-
ive approaches. For example, in addition to simulating the effect
f a knock out of given genes or combinations thereof, the effect of
 partial loss of function induced by a drug can also be simulated.
imulating the effect of decreasing the function of enzymes that can
e targeted with known drugs can highlight alternative metabolic
scape routes that become more relevant under these conditions
aving the way to the development of more efﬁcient therapeutic
trategies.
Here we present a new genome-scale CB model of Mtb
etabolism, sMtb (in silico Mycobacterium tuberculosis), which
uilds upon three previously published models and which is experi-
entally validated in great detail. Our model also includes recently
iscovered or annotated reactions and pathways, has undergone
xtensive manual curation and outperforms its predecessors in
erms of both qualitative and quantitative predictions. We  discuss
he applications of this model for the identiﬁcation of possible drug
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targets, to the unraveling of potentially unknown interconnections
and for the development of future intervention strategies.
2. Mathematical models of metabolism
There are different types of metabolic models, all of them
based on networks of metabolites that are interconnected through
enzymatic, spontaneous, or transport reactions. These metabolic
networks are reconstructed from literature and annotated genome
data.
CB metabolic models are stoichiometric, mass, charge and
energy-balanced scaffolds that describe steady-state kinetics,
whereas dynamic metabolic models are explicitly time-dependent
and enable to determine the changes in the concentration of
metabolites over time. Thus, dynamic metabolic models enable
more accurate descriptions of metabolism, but require many
detailed kinetic parameters, such as rate-constants of every
enzyme. Such kinetic parameters are often unknown and obtain-
ing them experimentally is often difﬁcult or impossible. Therefore,
for a genome-scale dynamic model, many of these parameters are
unavailable and many of them would have to be ﬁtted to the
model, which would diminish its predictive power. In addition,
simulations with these models are computationally costly, mak-
ing dynamic models thus far unsuitable to describe metabolism on
a genome-scale.
Genome-scale CB metabolic modeling provides a holistic view
on metabolism and transport. A metabolic network forms the foun-
dation of a CB metabolic model (Fig. 1). The stoichiometry of
each reaction is written in a stoichiometric matrix where negative
numbers represent the consumption of metabolites and positive
numbers represent the formation of metabolites. This stoichiomet-
ric matrix ensures that the system is in steady-state, as for every
reaction no metabolite can accumulate. Through the application of
constraints, hence they are called ‘constraint-based’, the number of
possible metabolic states can be lowered, to best predict the actual
metabolic state of an organism under given genetic and environ-
mental conditions [13]. Applying too many constraints can result
in an infeasible model where no possible metabolic state can be
found. CB metabolic models can be used to predict genes [14] and
metabolites that are essential to synthesize precursors for growth
[15]. A major advantage of genome-scale CB metabolic models as
compared to dynamic models is that few parameters are required to
describe the entire known metabolism of an organism. On the other
hand, CB metabolic models are not easily adapted to describe the
dynamics of the system, since they contain a stoichiometric matrix
and are thus designed to operate in steady-state conditions where
uptake and secretion ﬂuxes are constant and there is no net accu-
mulation of metabolic intermediates, which is only valid if the time
scales under consideration are different enough. These metabolic
models are based on optimization principles and need one or more
optimization objectives to function. Optimization objectives in CB
metabolic models can be multiple and describe what the organism
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aims’ for. Examples of frequently used metabolic objectives are:
aximizing the speed at which an organism grows, maximizing
he production of energy carrying metabolites (such as ATP), and
inimizing the overall usage of enzymes [16].
.1. Flux predictions
Flux is a commonly used concept in physics where it is deﬁned
s the rate of ﬂow of a magnitude or property through a deﬁned
rea [17]. In the realm of CB metabolic models, this term is used
o indicate the rate of conversion of one metabolite to another
er unit of biomass (usually given in mmol  gdw−1 h−1, where gdw
enotes grams of cell dry weight). For transport reactions, there
s no metabolite conversion and the term ﬂux refers to the rate
f transportation between cellular or sub-cellular compartments.
luxes can have positive or negative values in CB metabolic models,
epending on whether a forward or reverse reaction is predicted.
he metabolic state, ﬂux state or ﬂux distribution of an organism is
eﬁned as the whole of all ﬂuxes throughout metabolism [18,19].
onstraints can be placed on some of these ﬂuxes (e.g. the uptake
nd secretion rates) to limit the model. These constraints reﬂect
he limitations of enzymes, transport proteins or nutrients and lead,
pon optimization of one or multiple objectives, to meaningful ﬂux
istributions.
.2. Objective functions
An important assumption of CB metabolic models is that opti-
ization principles underpin metabolic states. In other words, the
odel assumes that a cell ‘strives to achieve a metabolic objective’
20]. CB metabolic models are underdetermined and can be solved
athematically, which requires the optimization of one or multi-
le objective functions. Most genome-scale CB metabolic models
ontain one or multiple biomass functions. A biomass function is
n integral part of a CB metabolic model and entails the amount
in mmol) of metabolites that are required to form 1 g dry weight
f biomass and as such represents growth of the organism. The
mounts of the individual metabolites are usually based on liter-
ture about the organism and vary for different reconstructions.
aximization of the ﬂux through the biomass function thus leads
o a prediction of the metabolic state when maximal growth is
chieved, given a deﬁned set of available nutrients.
Schuetz and colleagues [16] used a model of the central carbon
etabolism of Escherichia coli to systematically compare ﬂux distri-
utions, resulting from 11 objective functions, to 13C-determined
n vivo ﬂux distributions from six growth conditions. They con-
luded that no single objective best describes all conditions and
he most relevant objective for each condition has to be identiﬁed.
.3. Solution space
The solution space of a CB metabolic model (represented as a
ashed cube in Fig. 1) is deﬁned as the range in which ﬂuxes can
ary while leading to the optimal value of the objective function. An
nherent property of CB metabolic models is the fact that, even after
ptimizing a given objective function, the solution space remains
argely undetermined. This region of feasible metabolic ﬂux distri-
utions grows larger with increasing model size and reﬂects the
etabolic ﬂexibility of living organisms. Once the solution space
as been deﬁned, Markov chain Monte Carlo sampling [21] or vari-
tions thereof [22] can be used to obtain probability distributions
or the ﬂuxes and extract descriptors (such as means and standard
eviations) for these distributions. Such an approach gives an indi-
ation of which ﬂuxes can be accurately determined under a given
et of constraints, and which cannot. Moreover, an estimation of themunology 26 (2014) 610–622
signiﬁcance of the change of each ﬂux between different conditions
can be provided.
2.4. Predictions of speciﬁc growth rates
CB metabolic models can quantitatively predict speciﬁc growth
rates, or growth yields. Therefore, a comparison between predicted
and experimentally determined values, such as the speciﬁc growth
rate, provide the means to test the accuracy of the model. Con-
straints are set on the set of experimentally measured uptake
and/or secretion rates while the uptake of other available metabo-
lites (if any) is left unconstrained. Subsequently, the biomass
function is set as the objective to maximize, which results in a
predicted maximal speciﬁc growth rate.
These quantitative validations are limited since only one pre-
dicted ‘ﬂux’ value, the speciﬁc growth rate, is compared to
experimental data. Due to the inherent uncertainty provided by the
size of the solution space, not all metabolic ﬂuxes can be predicted
with equal accuracy. However, many of these ﬂuxes can still be pre-
dicted within a narrow range. Comparing multiple predicted ﬂuxes
to experimentally measured or experimentally inferred ﬂuxes pro-
vides a much more solid and quantitative validation of CB metabolic
models.
2.5. The importance of updating models
An example that illustrates the importance of updating CB
metabolic models is the conversion of fructose-6-phosphate to
fructose-1,6-bisphosphate catalyzed by PfkA and/or PfkB in Mtb.
Within different models, the enzymes and their interaction in cat-
alyzing this ATP driven reaction are annotated differently. In one
Mtb  model this reaction can only occur if PfkA and PfkB are both
present, while in another this reaction can occur if either PfkA
or PfkB is present [23,24]. However, Phong and colleagues [25]
showed that only PfkA catalyzes the conversion of fructose-6-
phosphate to fructose-1,6-bisphosphate whereas PfkB does not.
Thus, clearly both models should be updated. This is one of the
examples that show that it is important not only to create consis-
tent models, but also to continuously update them. CB metabolic
models organize and integrate the knowledge on metabolism and
transport into a well-deﬁned network. Therefore, CB metabolic
models enable to systematically explore the metabolic capaci-
ties of organisms under a broad range of conditions and allow
assessing the effect of perturbations (genetic or environmental)
on the underlying metabolic network. On the basis thereof, these
analyses subsequently enable generating experimentally testable
hypothesis, making predictions over a range of conditions and
provide invaluable insights that cannot be obtained if not from a
systems perspective.
2.6. Merging of metabolic models
Two or more independently created CB metabolic models of the
same organism will likely contain many common reactions and
metabolic pathways. Owing to the speciﬁc emphasis and exper-
tise of the model builders, it is also likely that both models would
describe different parts of metabolism or the same pathways with
different detail level. To preserve the knowledge in these models, a
logical step is combining them into one comprehensive or consen-
sus model. Merging two  or more CB metabolic models describing
the same organism might seem, at ﬁrst sight, a straightforward
task. Nevertheless, it can prove quite time consuming and full of
unexpected challenges, such as those associated with the so-called
namespace problem, derived from using different names for the
metabolites [26]. This complicates the automatic identiﬁcation of
compounds common to both models. This implies that manual
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uration is still required to identify similar reactions and remove
iscrepancies.
.7. Topological and elemental balancing inconsistencies
In a CB metabolic model all reactions must be stoichiomet-
ically balanced so that there is no net internal production of
ny metabolite. Software tools, such as the COBRA Toolbox [27]
nclude functionalities to inspect the model and detect unbalanced
eactions. These tools require all metabolites in the model to be
nnotated with their chemical formula, which is the case for iNJ661
ut not for GSMN-TB 1.1. Moreover, GSMN-TB 1.1 does not explic-
tly contain water or protons (apart from transport reactions and
espiration), making it impossible to verify whether the reactions
re elementally balanced.
Futile cycles are metabolic routes with no net gain. The exist-
nce of futile cycles in a metabolic network expands the solution
pace and complicates ﬂux predictions. In some cases, these cycles
re inherent to the biology of the studied organism. However, they
an also appear as a result of an overlooked doubling of reactions,
r by wrongly assigned reaction directionality. These types of futile
ycles are harmless from the model point of view, as long as they
o not lead to net production or degradation of metabolites. Oth-
rwise, they render the model unbalanced and model predictions
an become unreliable.
.8. History of CB metabolic models of Mycobacterium
uberculosis
Fig. 2 shows the timeline of the successive CB models of Mtb
etabolism that have been reconstructed since 2005. The very ﬁrst
B metabolic model described the synthesis of triacylglycerol from
lucose in human adipose tissue in 1986 [28]. Nearly two  decades
ater, in 2005, the ﬁrst CB metabolic model of Mtb  appeared [14].
his model (MAP) was a detailed description of the mycolic acid
ynthesis pathway. Mycolic acids are long chain fatty acids that are
nique to mycobacteria and essential for their survival [29]. In 2007,
wo genome-scale CB metabolic models of Mtb  were independently
ublished. Even though both models, GSMN-TB (Genome Scale
etabolic Network Tuberculosis) [30] and iNJ661 (in silico Neemaamshidi, 661 genes) [23], describe the same organism, there are
 number of substantial differences between them. GSMN-TB is
rguably more complete than iNJ661, as it contains more genes
726 as compared to 661) and it also accounts for the methylcitrate
ig. 2. Time line of CB metabolic models of Mtb. The numbers below every model
ame denote the number of genes, the number of reactions and the percent-
ge of gene-associated reactions in the model. MAP: mycolic acid pathway [14],
SMN-TB: genome-scale metabolic network of M.  tuberculosis [30], iNJ661: in silico
eema Jamshidi 661 genes [23], MMF-RmwBo: merged McFadden-Ramam with
iomass objective [32], iNJ661v: in vivo compatible model based on iNJ661 [33],
AB-AMØ-1410Mt-661: in silico Aarash Bordbar alveolar macrophage 1410 genes
ycobacterium tuberculosis 661 genes [7], MergedTBModel: merged Mycobacterium
uberculosis model [35], GSMN-TB 1.1: a curated and extended version of GSMN-TB
24], sMtb: in silico Mycobacterium tuberculosis.munology 26 (2014) 610–622 613
cycle, which is critical for intracellular growth of Mtb [31]. iNJ661
has a more detailed annotation containing chemical formulas for
each metabolite (except for some groups of metabolites that are
lumped together and protein-metabolite complexes) and it is topo-
logically more consistent, since it contains no duplicated reactions
or metabolites. In 2009, Colijn and colleagues [32] metabolically
interpreted gene expression data to predict the impact of 75 dif-
ferent drugs, combinations of drugs and media compositions on
the mycolic acid synthesis capacity of Mtb. The mycolic acid syn-
thesis pathway is described with greater detail within MAP  than
in GSMN-TB. Therefore, all mycolic acid reactions in GSMN-TB
were replaced with the mycolic acid reactions from MAP  creat-
ing a more comprehensive model (indicated by MMF-RmwBo  in
Fig. 2). In the beginning of 2010, Fang and colleagues [33] used a
semi-automatic method to create a model more compatible with
in vivo conditions, iNJ661v, which optimally reproduced in vivo
gene essentiality measurements. For completeness, this model was
supplemented with reactions and metabolites from GSMN-TB and
with the methylcitrate cycle. In the same year, Bordbar and col-
leagues [7] created the ﬁrst macrophage-Mtb combined model.
This dual model combined iNJ661 with a cell-speciﬁc alveolar
macrophage model derived from the ﬁrst human metabolic recon-
struction [34]. High-throughput host gene expression data from ex
vivo infected macrophages were integrated in the model to dis-
tinguish three different forms of tuberculosis: latent, pulmonary
and meningeal. In 2011 Chindelevitch and colleagues developed
MetaMerge, an algorithm to combine two  CB metabolic models,
and used it to merge iNJ661 and GSMN-TB [35]. The joining of
both models by MetaMerge is an automated process, therefore
manual curation is still required to select correct reactions from
highly similar reactions derived from both models and to identify
metabolites that could not automatically be assigned to a database
identiﬁer, or whose chemical formula could not be determined. In
2013, an improved and extended version of GSMN-TB, GSMN-TB
1.1 appeared [24]. GSMN-TB 1.1 contains the cholesterol degrada-
tion pathway and additional corrections to the original GSMN-TB
model.
2.9. Biomass functions for in vitro Mtb
iNJ661 and GSMN-TB 1.1 are reconstructed independently and
therefore not only differ in network topology, but also differ in the
biomass functions. The chemical formulas of all biomass precur-
sors in a CB metabolic model, multiplied with their stoichiometric
coefﬁcients, should add up to 1 g dry weight of biomass. This is the
case for the biomass functions of iNJ661 and sMtb and the contri-
bution of each subgroup of metabolites to the total biomass can
be calculated (Table 1). However, the weight percentage of nucleic
acids in iNJ661 seems to be up to ﬁve-fold higher than those used
in GSMN-TB 1.1. This difference can be attributed to differences
in two studies reporting on nucleic acid dry weight percentages
[36,37]. Unfortunately, there are no chemical formulas provided in
Table 1
Weight percentages of different biomass components.
Metabolite group Percentage of iNJ661
biomass (%wt/wt)a
Percentage of sMtb
biomass (%wt/wt)a
Amino acids 27 22
Nucleic acids 26 5
Sugars and carbohydrates 21 26
Lipids 25 39
Other 1 8
a The weight percentage of each subgroup of metabolites is calculated by multi-
plying the stoichiometric coefﬁcients for each metabolite in each subgroup by their
molecular weights and dividing the total in each subgroup by the total weight of all
metabolites.
6  in Immunology 26 (2014) 610–622
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Table 2
Validation of network topology and biomass function by gene essentiality. Note that
due to rounding, the totals may  not add up to 100%.
Model iNJ661 GSMN-TB 1.1a sMtb
Objective for in vitro growth No Yes Yes
True positives 132 20% 175 23% 215 23%
True negatives 288 44% 395 52% 522 57%
False positives 59 9% 45 6% 45 5%
False negatives 182 28% 144 19% 133 15%
Correct predictions 420 64% 570 75% 737 80%
Sensitivity 42% 55% 62%
Speciﬁcity 83% 90% 92%
For iNJ661, GSMN-TB 1.1 and sMtb this chance equals 0.65, 0.7814 R.A. Rienksma et al. / Seminars
SMN-TB 1.1, which complicates the identiﬁcation of the exact
ature of some compounds, such as ‘DIM’ (dimycocerosate) or
PIMS’ (phosphatidyl myo-inositol mannosides), and such a clas-
iﬁcation of the relative contribution of subgroups of metabolites
o biomass cannot be obtained. Biomass functions are often used
o validate CB metabolic models by comparing predicted speciﬁc
rowth rates with experimentally obtained speciﬁc growth rates.
NJ661 was validated in such a way, for growth on three media
iffering in carbon and nitrogen sources [23]. Similarly GSMN-TB,
he predecessor of GSMN-TB 1.1 was validated using experimen-
ally measured speciﬁc growth rates for various measured glycerol
ptake rates [30].
For sMtb, the biomass composition is based on the average com-
osition measured at two different growth rates [36], although
daptations would be required for those conditions where experi-
ental evidence shows altered compositions. Objective functions
or dormant mycobacteria are most likely very different from those
f actively replicating mycobacteria.
.10. Biomass functions for in vivo Mtb
Biomass composition of Mtb  is not constant over different condi-
ions. For instance it is known that Mtb  accumulates triacylglycerol
nder in vitro conditions that produce a state which mimics the
ormant state in the host [38], and that the synthesis of a speciﬁc
lass of iron chelating molecules, called mycobactin siderophores,
s required for iron acquisition [39]. These adaptations effectively
hange the biomass composition. Moreover, in vivo Mtb  is under
onstant stress caused by the host immune system, in particular
xidative stress by reactive oxygen and nitrogen species produced
y the host [40]. The damaging effects of these reactive species must
e compensated, again changing the growth requirements, which
hould be reﬂected in the optimization objective(s) when in vivo
etabolic states are simulated.
. A consensus metabolic model of Mtb  (sMtb)
The mere existence of eight different genome-scale metabolic
odels of Mtb, of which most are extensions of previous ones,
eﬂects the importance of keeping CB metabolic models up to date.
wo major independently created CB models of Mtb  metabolism
ave thus far not been merged and manually curated. These two
odels: GSMN-TB 1.1 and iNJ661 differ in size and cover partly
verlapping parts of Mtb  metabolism. Metabolites are annotated
ifferently for both models. Model iNJ661 contains for the metabo-
ites: abbreviations, full names, chemical formulas and charges,
hereas GSMN-TB 1.1 only contains abbreviations and full names.
oth models use different abbreviations and few metabolite names
ppear the same in both models. Neither model contains references
o persistent chemical databases, such as ChEBI [41], PubChem [42]
r KeGG [43] or database-independent identiﬁers, such as SMILES
44]. There are large parts of metabolism covered by GSMN-TB
.1 that are not covered by iNJ661 and vice versa. In addition,
he mycolic acid synthesis pathway is described in more detail
y model MAP  than either iNJ661 or GSMN-TB 1.1. Therefore we
ave constructed sMtb, a manually curated merged model of MAP,
NJ661 and GSMN-TB 1.1 that is currently the most comprehen-
ive genome-scale metabolic model of Mtb. sMtb is provided in
he supplementary material in SBML formats, level 2 and 3 and
s a spreadsheet. Unlike previously published CB metabolic Mtb
odels, sMtb contains chemical formulas, references to KeGG,
ubChem, ChEBI and SMILES for all metabolites. These references
ermit automated reasoning and allow all reactions to be ele-
entally balanced. The metabolic network of sMtb contains 1192
eactions, 915 genes, and 929 metabolites. It includes a number ofAccuracy 64% 75% 80%
a TP, TN, FP, FN and correct predictions percentages from [24].
important extensions to previous models, such as the mycolic acid
synthesis [29], dimycocerosate ester biosynthesis [45] and choles-
terol degradation [8] pathways that have been updated according
to the latest insights. In sMtb 84% of the reactions are associated
with the corresponding genes, whereas in GSMN-TB 1.1 and iNJ661
these percentages are only 75% and 77%, respectively. A high per-
centage of gene-associated reactions in a CB metabolic model is a
signature of a reliable network topology. However, it is not a guar-
antee, because the gene essentiality predictions of GSMN-TB 1.1
are better than those of iNJ661 (Table 2). This does not necessar-
ily mean that the network topology of GSMN-TB 1.1 is better than
that of iNJ661, it could also be due to the more accurate biomass
objective of GSMN-TB 1.1 that is designed to describe in vitro
growth.
3.1. Prediction of gene essentiality
Gene essentiality predictions depend, among other factors, on
the available nutrients, the topology of the metabolic network, the
quality of the annotation and the chosen objective function. These
predictions are suitable to test the topology of a metabolic net-
work, however, they are by no means a quantitative validation of
ﬂux distribution predictions. Genes are deleted from the model one
at the time and all the reactions that are dependent on the enzyme
encoded by the gene are constrained to carry no ﬂux. If the value of
the objective function (often maximization of biomass production)
is signiﬁcantly or totally reduced by these constraints, the gene
is predicted to be essential. These predictions are thus condition
speciﬁc and differ for the various models. We  have used iNJ661,
GSMN-TB 1.1 and sMtb to predict genes that upon in silico dele-
tion would result in a decrease of the speciﬁc growth rate by 95%
or more (see supplementary methods). Those genes were said to
be essential and compared to an in vitro gene essentiality dataset
generated via deep sequencing [5]. It can be seen in Table 2 that
sMtb performs best in predicting in vitro gene essentiality, with an
accuracy of 80% as compared to 75% for GSMN-TB 1.1 and 64% for
iNJ661.
However, as the chosen threshold changes, so do the sensitiv-
ity (also called true positive rate) and the false positive rate (1 –
speciﬁcity). The relationship between the false positive rate and
the true positive rate for the gene essentiality predictions by the
various models for different threshold values is given in a Receiver
Operating Characteristic (ROC) curve (Supplementary Fig. 2). The
corresponding Area Under the Curve (AUC) represents the chance
that a randomly chosen experimentally observed essential gene is
predicted as such and is commonly used for model comparison.and 0.80 respectively. In all three cases the p-values (all lower than
10−5) associated with the AUC show that these areas are signif-
icantly different from 0.5, which would correspond to a random
prediction.
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Table  3
Growth related ATP coefﬁcients and speciﬁc growth rate predictions for the various models.
Model Growth related coefﬁcient (mmol gdw−1) Speciﬁc growth rate prediction (h−1)
0.01 BCG 0.03 BCG 0.01 Mtb
iNJ661 60 0.0137 0.0155 0.0077
GSMN-TB 1.1 47 (+9a) 0.0037 0.0070 0.0037
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is complicated due to the fact that iNJ661 does not contain a choles-
terol degradation pathway, which has been shown to be important
for intracellular growth and survival [8,52–56]. Mtb  infection is a
Table 4
Pearson’s correlation coefﬁcient for inferred and predicted ﬂuxes for BCG and Mtb
at  various growth rates.
Model Pearson’s correlation coefﬁcientsMtb  57 
a Excluding ATP costs for protein, RNA, and DNA synthesis. The sum of these cost
.2. Central carbon metabolic ﬂux predictions compared to 13C
ata
To validate CB metabolic models, ideally the predicted metabolic
tates would be compared to measured metabolic states. Although
etabolic states cannot directly be measured, they can be inferred
y isotopic labeling experiments. Flux distributions obtained from
tb  CB genome-scale metabolic models have thus far not been
ompared to in vitro 13C inferred ﬂuxes as has been done for other
rganisms, such as E. coli [16,46].
We  compared the ability to correctly predict metabolic ﬂux dis-
ributions for the three CB metabolic models: iNJ661, GSMN-TB 1.1
nd sMtb. In vitro results for Mtb  and the attenuated TB vaccine
train Mycobacterium bovis Bacillus Calmette-Guérin (BCG) were
btained from Beste et al. [47]. BCG has a high degree of genome
dentity to Mtb  and is therefore often used as an Mtb  surrogate
48–50]. The three CB metabolic models GSMN-TB 1.1, iNJ661 and
Mtb all contain biomass functions that are based on both BCG and
tb  biomass composition. Therefore, metabolic ﬂuxes from both
tb  and BCG are used. Beste and colleagues measured the spe-
iﬁc glycerol consumption rate, the speciﬁc Tween 80 consumption
ate and the speciﬁc CO2 production rate at two different dilution
ates: 0.01 h−1 and 0.03 h−1 for BCG and 0.01 h−1 for Mtb  [47]. These
xperiments were done in a chemostat, therefore the dilution rate
quals the speciﬁc growth rate. Tween 80 is a fatty acid ester of sor-
itan polyethoxylate. Mycobacteria have phospholipase A activity
hat release fatty acids from Tween [51]. In the case of Tween 80,
leic acid is released. Therefore, the speciﬁc consumption rate of
ween 80 can be simulated as the speciﬁc consumption rate of oleic
cid (for more details see supplementary methods).
Non-growth associated maintenance is expressed as a conver-
ion of ATP to ADP and quantiﬁes the energy required by Mtb
o maintain itself in a given environment. All models gave the
est speciﬁc growth rate prediction when the non-growth asso-
iated maintenance was set to 0 mmol  gdw−1 h−1 (Supplementary
ig. 1). However, a small amount of energy for maintenance is
lways required to sustain an organism in its environment, there-
ore a small arbitrary maintenance ﬂux of 0.1 mmol  gdw−1 h−1
as included in each model before predicting the optimal speciﬁc
rowth rate to compare with the measured values (Table 3).
As can be seen in Fig. 3, predicted ﬂuxes and 13C inferred in vitro
uxes in general do not completely agree. The different path-
ays in central carbon metabolism are separated in Fig. 4 and
he predictions of the different models are given. Metabolic path-
ay representations of the metabolic state predictions are given
n Supplementary Figs. 3–5. All models predict a low ﬂux through
he pentose phosphate pathway, even though 13C inferred ﬂuxes
how otherwise for BCG at a speciﬁc growth rate of 0.03 h−1, but
how completely different behaviors for the tricarboxylic acid cycle
nd the glyoxylate shunt (Fig. 4). The discrepancies between 13C
nferred ﬂuxes and the ﬂux predictions by the various models show
hat the predictions of the models become worse as the distance
i.e. the number of reactions) from the glycerol entry point, where
lycerol is converted to glycerol-3-phosphate, increases. The pre-
ictions for pathways such as the TCA cycle and glyoxylate shunt
re worse than those for glycolysis and glycerol uptake, because0.0151 0.0260 0.0129
ls approximately 9 mmol gdw−1 h−1.
they are further ‘downstream’ of the glycerol entry point in the
models and thus more options exist for the ﬂux to be rerouted
toward alternative parts of the metabolic network that are not
shown in the network depicted in Fig. 3. Model sMtb does relatively
well at ﬂux predictions for glycolysis and the TCA cycle. In contrast
to iNJ661 and GSMN-TB 1.1, it is the only model that predicts a ﬂux
from pyruvate to acetyl-CoA for BCG at a speciﬁc growth rate of
0.03 h−1 and Mtb  at a speciﬁc growth rate of 0.01 h−1. The standard
deviations for most predicted ﬂuxes are relatively small (given by
error bars in Fig. 4), implying that the predictions are precise but not
accurate. This could be partly due to the applied sampling method
to determine means and standard deviations (see Supplementary
methods), but it could also be caused by a bimodal distribution
of ﬂux solutions instead of a normal distribution, which would
limit the usefulness of concepts such as means and standard devi-
ations. Another point to consider regarding ﬂux predictions is that
although the ﬂux predictions of all three models can be improved,
13C ﬂuxes are also inferred from a model, using measured metabo-
lites, which makes it more complicated to point out whether the
predicted ﬂuxes, inferred ﬂuxes, or both can be improved.
Nevertheless, sMtb shows the highest agreement between
inferred and predicted ﬂuxes, closely followed by iNJ661 (Table 4).
The more accurately reﬂected cellular behavior under in vitro con-
ditions by sMtb as compared to iNJ661 and GSMN-TB 1.1 increases
the conﬁdence of predictions of cellular behavior under in vivo con-
ditions by sMtb. Therefore, sMtb provides a more accurate platform
for drug target discovery than was  available before.
3.3. Drug–phenotype predictions
We tested the three models on their ability to assess the effec-
tiveness of anti-TB drugs with known metabolic targets. Table 5
provides an overview of the predicted phenotypes after drug appli-
cation by inactivating the speciﬁc enzyme and the corresponding
reaction(s) in silico (see supplementary methods). sMtb predicts
the highest number of non-viable phenotypes caused by anti-TB
drugs, closely followed by iNJ661 and GSMN-TB 1.1. Neverthe-
less, these predictions are based on growth on Roison’s minimal
medium [47], which does not represent in vivo conditions. More-
over, in vitro biomass functions are used for both GSMN-TB 1.1 and
sMtb. Setting the models such that they simulate in vivo condi-
tions would alter these drug–phenotype predictions. However, thisBCG  = 0.01 h−1 BCG  = 0.03 h−1 Mtb   = 0.01 h−1 Average
iNJ661 0.87 0.90 0.94 0.90
GSMN-TB 1.1 0.42 0.80 0.90 0.66
sMtb 0.90 0.95 0.98 0.94
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Fig. 3. Central carbon metabolism and agreement between 13C inferred and predicted ﬂux. Central carbon metabolism of BCG and Mtb  is given on the left. For each reaction a
gene  name and a locus tag is given corresponding to the gene(s) encoding the enzyme(s) catalyzing the reaction. Isozymes are indicated separated by a ‘|’ while subunits are
separated by a ‘&’ symbol. The graphs on the right indicate the agreement between 13C inferred [47] ﬂuxes and predicted ﬂuxes by iNJ661 (crosses), GSMN-TB 1.1 (triangles)
and  sMtb (plusses). The ﬂuxes are given as a percentage of the glycerol uptake rate. Negative percentages denote a reversed ﬂux direction. The black dashed line represents
perfect  agreement. Metabolite abbreviations: GL, glycerol; G6P, d-glucose 6-phosphate; F6P, d-fructose 6-phosphate; FBP, d-fructose 1,6-bisphosphate; G3P, d-glyceraldehyde
3-phosphate; 13PDG, 3-phospho-d-glyceroyl phosphate; 3PG, 3-phospho-d-glycerate; 2PG, 2-phospho-d-glycerate; PEP, phosphoenolpyruvate; PYR, pyruvate; D6PGL,
d se 5-p
t rate; 
f
c
c
h
a
d
m
s
a
p
a-glucono-1,5-lactone 6-phosphate; D6PGC, 6-phospho-d-gluconate; RL5P, d-ribulo
ulose  7-phosphate; E4P, d-erythrose 4-phosphate; ACCOA, acetyl-CoA; ICIT, isocit
umarate; MAL, malate; OA, oxaloacetate; GLX, glyoxylate.
omplex interplay between the pathogen and its host that involves
ellular changes in both organisms [57]. Therefore, modeling both
ost and pathogen metabolism simultaneously is required for an
ccurate representation of infection.
While CB metabolic models unfortunately cannot directly pre-
ict which molecules are effective drugs, they can predict which
etabolic enzymes make for suitable drug targets. Whether or notuch enzymes can be effectively inhibited depends on the char-
cteristics of the enzyme itself. Databases such as TuberQ [58] can
rovide a druggability analysis for an enzyme predicted to be a suit-
ble drug target, thereby verifying if the enzyme can effectively behosphate; X5P, d-xylulose 5-phosphate; R5P, d-ribose 5-phosphate; S7P, sedohep-
AKG, 2-oxoglutarate; SUCSA, succinic semialdehyde; SUCCOA, succinyl-CoA; FUM,
targeted. An approach to select suitable drug targets will be more
effective if essentiality analysis is combined with additional sys-
tems level information such as information on the accumulation of
stable toxic intermediates. For example, the cholesterol degrada-
tion pathway in Mtb  [8] contains a large number of enzymes, many
of them essential for cholesterol degradation and thus possible drug
targets. However, stable toxic intermediates such as cholest-4-en-
3-one and catechol derivatives accumulate if the enzymes HsaC,
KshA, Cyp125 and Cyp142 are non-functional [59,60]. The accu-
mulation of such intermediates can be fatal to Mtb, increasing the
potential of these enzymes as drug targets. A similar approach can
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Table  5
Drugs with known metabolic targets [6,83–85] and the percentage of the speciﬁc growth rates obtained after in silico gene knockouts of these targets.
Target Drug Percentage of the wild type speciﬁc growth rate obtained
iNJ661 (%) GSMN-TB 1.1 (%) sMtb (%)
InhA Isoniazid, ethionamide 0 100 0
KasA  Isoniazid 0 100 0
DfrA  Isoniazid 0 100 100
EmbB  Ethambutol 0 0 0
Alr  Cycloserine 0 0 0
DdlA  Cycloserine 0 0 0
FolP1  Para-amino salicylic acid 100 100 100
AtpE  TMC207 63 57 60
DprE1 BTZ043 100 0 0
KasB  Thiolactomycin 0 100 0
FabH  Thiolactomycin 100 0 100
MmaA4 Thiacetazone 100 0 0
Total  percentage of non-viable phenotypesa 58 50 67
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pa If the predicted speciﬁc growth rate of an in silico knockout mutant equals 5% 
lassiﬁed as a non-viable phenotype.
e taken by designing replacement substrates for enzymes that
erve as inhibitors of subsequent enzymes after being activated by
he target enzyme [61].
Perhaps one of the biggest advantages of using CB metabolic
odels to ﬁnd drug targets is that it enables the prediction of
etabolic rearrangements after constraining the ﬂux through reac-
ions that are known to be affected by a given drug. This can
ighlight the possible ‘escape routes’ that Mtb  possesses. Bhat and
olleagues [12] used such an approach which is further discussed
n Section 4.7.
.4. sMtb overall performance
Model iNJ661 predicts metabolic states relatively well as com-
ared to GSMN-TB 1.1 (Table 4, Figs. 3 and 4), but on the other hand
he gene essentiality predictions of GSMN-TB 1.1 are better (accu-
acy of 75%) than those of iNJ661 (accuracy of 64%). The consensus
enome-scale CB metabolic model sMtb is the most comprehen-
ive, manually curated genome-scale CB model of Mtb  to date. It
epresents the strengths of iNJ661 and GSMN-TB 1.1 and not only
ives accurate qualitative predictions, such as gene essentiality pre-
ictions (Table 2) and drug–phenotype predictions (Table 5), but
lso accurate quantitative predictions, such as the speciﬁc growth
ate (Table 3) and the metabolic states (Fig. 4; Supplementary Figs.
–5). The overall improved performance of sMtb is essential for
btaining meaningful and accurate predictions of the metabolic
tate in conditions that are experimentally inaccessible. Moreover,
he improved annotation of sMtb regarding its metabolites is a crit-
cal point, as it enables future reﬁnements and extensions by other
esearchers with relative ease.
However, even though sMtb performs better in overall predic-
ions of in vitro metabolic states, there is room for improvement,
specially regarding the metabolic state predictions of the pentose
hosphate pathway and the glyoxylate shunt. Options to achieve
hese better predictions would be to supply a more accurate objec-
ive, or to improve the underlying metabolic network of sMtb.
. Understanding Mtb  metabolism and designing
ntervention strategies: challenges and outlook
In an attempt to mimic  metabolic states of Mtb  in various envi-
onments more accurately, CB metabolic models can be constrained
ith various types of -omics data. Unlike ﬂux measurements, gene
xpression data can be relatively straightforwardly obtained using
NA sequencing or micro array technologies. CB metabolic mod-
ls can also act as scaffolds for other types of -omics data, such as
roteomics. These data types have the added advantage of beings of the in silico wild-type speciﬁc growth rate prediction, the knockout mutant is
(almost) genome-scale and can be integrated into CB metabolic
models, creating condition-speciﬁc models with increased pre-
dictive power. Such condition-speciﬁc models are important to
provide reliable metabolic state predictions in in vivo conditions
where uptake rates and metabolic objectives are unclear, with the
ultimate goal of designing novel intervention strategies.
4.1. Integration of expression data
Alternative methods have been developed to integrate either
gene or protein expression data into CB models, see [20,62–64] for
recent reviews. A systematic evaluation of these methods, compar-
ing performance and robustness using alternative models and data
sets [65] shows that no method outperforms the others in all the
tested scenarios. Here, we will focus on the methods that have been
applied to explore mycobacterial metabolism.
E-Flux [32] constrains the maximum ﬂux through a reaction
using the measured gene expression levels. Whenever the expres-
sion level of an enzyme-coding gene is low, tight constraints are
imposed on the maximal ﬂux through the corresponding reaction.
The rationale is that mRNA levels can be used as an approximation
to the amounts of protein available, and these in turn can be used
as an approximation to the upper bound on reactions rates. This
algorithm was tested using two  models, MAP and MMF-RmwBo.
The Boshoff Mtb  gene expression compendium [66] contains over
400 microarray experiments measuring the transcriptional adap-
tations of Mtb  to 75 different drugs, drug combinations and growth
conditions. E-Flux was used to predict the impact of each of these
conditions and drugs on the biosynthesis of mycolic acids. This
approach correctly predicted the speciﬁcity of seven of the eight
known inhibitors of mycolic acid biosynthesis included in the data
compendium. Additionally, it was  also able to identify a small num-
ber of non-speciﬁc potential inhibitors and enhancers of mycolic
acid biosynthesis.
While E-Flux uses transcript data to improve the predictions
of metabolic ﬂuxes, Fang and colleagues [67] proposed an in
silico approach to create state-speciﬁc models by integrating gene
expression data. Their method relies on comparing gene expres-
sion levels between a metabolically well-characterized reference
state and the perturbed state of interest. This method uses the
ﬂux distribution in the reference state and imposes soft constraints
on the ﬂuxes according to the observed changes in gene expres-
sion to characterize the perturbed metabolic state. Changes in gene
expression data for wild type Mtb  H37Rv, as well as for the dosR
deletion mutant, associated with the transfer from normoxic to
hypoxic conditions were combined with iNJ661v to produce con-
dition speciﬁc models for both strains. These models correctly
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redicted the essentiality of dosR for the adaptation to hypoxia.
dditionally, the model also predicted the altered biomass com-
osition of Mtb  in hypoxic conditions (linked to the increased
roduction of cell-wall metabolites) and the critical contribution
f the reductive side of the tricarboxylic acid cycle to the adapta-
ion to low oxygen environments. The condition speciﬁc models can
lso serve to speciﬁcally identify drug targets for the latent stages
f the disease.
The algorithms described so far provide as primary output
odels of metabolism with altered constraints that can be used
o further characterize the metabolic responses. Differential Pro-
ucibility Analysis (DPA) [68] on the other hand, aims at extracting
etabolic signals from expression data. DPA uses the model to
dentify genes affecting the production of each metabolite in the
etwork, then expression data is used to obtain and average expres-
ion values of each set of metabolite associated genes. These values
re then used to identify the metabolites associated with increased
nd decreased gene expression. DPA was used to analyze the
etabolic state of Mtb  in vivo (with expression data obtained from
putum samples of TB patients and from pathogens replicating
n mouse macrophages) [69,70] and in various in vitro conditions
such as growth on different carbon sources or exposure to dif-
erent stress sources) [66,71]. The analysis showed that one of the
ain adaptations to the macrophage environment is the down reg-
lation of genes inﬂuencing metabolites in central metabolism,
nd the simultaneous upregulation of genes linked to cell wall
ynthesis.
.2. Integration of regulatory information
Probabilistic regulation of metabolism (PROM) [19] is an algo-
ithm that attempts to link regulatory and metabolic networks.
he transcriptional regulatory network of Mtb  [72] and the Boshoff
tb  compendium [66] were used to build a probabilistic model
f gene regulation. The probabilities were then integrated into the
NJ661 model as constraints on reactions of which the ﬂux could
ary according to the state of the transcription factor regulating
he expression of the enzyme-coding gene. PROM correctly pre-
icted the phenotype of 23 out of the 24 studied transcription
actor knock out mutants. The increased knowledge on the reg-
latory networks in Mtb  [73] opens new ways to consider not
nly genes primarily related to metabolism but also to their reg-
lators, thereby increasing the potential to discover new drug
argets.
.3. Growth related ATP coefﬁcients and non-growth associated
aintenance
The biomass reaction describes the assembly of biomass precur-
ors into new cells. Each biomass precursor has a deﬁned coefﬁcient
enoting the amount (in mmol) required to form 1 g dry weight of
iomass. The assimilation of these precursors requires energy, in
he form of ATP to ADP conversion that is introduced through a
rowth related ATP coefﬁcient in the biomass function (also called
rowth associated maintenance). This coefﬁcient is very similar for
NJ661, GSMN-TB 1.1 and sMtb (Table 3). The growth related ATP
oefﬁcient of iNJ661 equals 60 mmol  gdw−1 and that of GSMN-TB
quals 47 mmol  gdw−1 plus an additional 8.8 mmol  gdw−1 associ-
ted with protein formation. Both models thus have a similar value
or growth-associated maintenance. Unlike the growth related ATP
ig. 4. 13C inferred ﬂuxes and predicted ﬂuxes for various parts of central carbon metabol
.1  (gray) and sMtb (light gray), given as a percentage of the glycerol uptake rate, for the 
nd Mtb  grown at 0.01 h−1. The error bars indicate the standard deviations.munology 26 (2014) 610–622 619
coefﬁcient, non-growth associated maintenance is independent
of the biomass composition. Instead, it depends on the environ-
ment and on the metabolic pathways utilized for growth [74]. It is
assumed that non-growth associated maintenance, in the form of
ATP to ADP conversion, is a ﬁxed value independent of the speciﬁc
growth rate. Here, we have set the non-growth associated main-
tenance to a small value so that the three models give the best
predictions of the speciﬁc growth rate (see Supplementary Fig. 1).
Non-growth associated maintenance is a useful parameter
when trying to simulate in vivo, e.g. phagosomal, growth. The
phagosome is a hostile environment and the energy required for
non-growth associated maintenance will be relatively high, com-
pared to in vitro growth conditions. Moreover, the speciﬁc growth
rate will be limited in the phagosome. A high non-growth asso-
ciated maintenance requirement and a low speciﬁc growth rate
cannot be simulated effectively using a model that contains a
regular biomass function, which includes a growth related ATP
coefﬁcient, but no non-growth associated maintenance cost.
4.4. Objective and constraints for Mycobacterium tuberculosis in
the host
When using CB genome-scale metabolic models of Mtb as
opposed to non-pathogenic microorganisms grown in an in vitro
condition, it is not straightforward to select an optimization objec-
tive. The primary objective of the pathogen might be focused on
survival instead of growth. In addition, the host-pathogen interac-
tion is a complex and time-dependent dynamic process, where they
mutually inﬂuence each other. Hence, CB metabolic models, which
rely on the steady state assumption, might not be realistic for many
pathogens. Mtb  is known for its ability to remain dormant in the
host for years. In those cases, the host’s immune system prevents
the pathogen from spreading and Mtb  is contained within solid
granulomas [2]. It is estimated that 2 billion people worldwide are
latently infected [1]. The relative metabolic activity at the latent
infection stage however, is very low. There is thus a stark need to
understand the mechanisms underlying dormancy and predict its
dynamics and the switch to active state. Modeling accurately and
realistically this infection stage is hence of utmost importance. A
key factor determining the accuracy of CB metabolic models in an
infection setting is the identiﬁcation of a suitable objective function
representing dormant Mtb. Shi and colleagues created an objec-
tive function representing non-growing cells, based on the minimal
cell wall composition deduced from gene expression data [75].
They compared predicted ﬂux changes between growing and non-
growing cells with qPCR data and found consistency between ﬂuxes
and gene expression for critical pathways of central metabolism. A
limitation of this approach is that the metabolic model is based
on transcript abundance data [75]. A leap forward would be to
investigate the biomass composition of Mtb  in an in vivo or ex vivo
situation.
Knowledge (or the lack thereof) of the availability of nutrients
in the host environment is another factor that determines the qual-
ity of the model predictions. Bordbar and colleagues constructed a
macrophage-Mtb model, iAB-AMØ-1410-Mt-661, they estimated
that the carbon sources available in the phagosome were glycerol
and even long chain fatty acids (myristic acid, palmitic acid and
stearic acid) [7]. Recent insights have changed this picture and high-
lighted the importance of cholesterol [8], aspartate [76], and other
nutrients [9] in the phagosomal environment. Knowing the precise
ism. 13C inferred [47] (black) and predicted ﬂuxes for iNJ661 (dark gray), GSMN-TB
various parts of central carbon metabolism for BCG grown at 0.01 h−1 and 0.03 h−1
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omposition and availability of such nutrients will enable to make
uch more accurate predictions of the in vivo metabolic state and
f the in vivo essentiality of gene products.
.5. Annotation of combinatorial proteins
Little is known about transport proteins of Mtb  despite the
bundance of genomic data [77]. Transport proteins are at the
oundaries of the metabolic networks and therefore function as
atekeepers for ﬂuxes. Not only is it important to know which com-
ounds Mtb  can take up, but it is also important to know whether
hese transporters are channels, symporters or antiporters. In addi-
ion, quantitative predictions also require the knowledge of the
nergy requirements of the transporters. A better annotation of
ransport proteins of Mtb  is therefore required.
.6. Cofactor limitation
Beste and colleagues mimicked the cofactor requirements of the
nzymes by forcing the reactions catalyzed by these enzymes to use
 small arbitrary amount of cofactor [30]. Quantitative predictions
re most likely not accurate due to the arbitrarily chosen amount
f cofactor used in any reaction. Nevertheless, such an approach
ould be extended to simulate cofactor limitations. Iron availability
s assumed to be reduced in the phagosome [69], thus introduc-
ng ways to mimic  this iron scarcity in the CB models, will lead to
ore accurate descriptions of the bacterial metabolism during the
nfection process.
.7. Discovering new drug targets and combinations of drugs
Fang and colleagues integrated a dynamic cell population
rowth model and an enzyme inhibition model with a modiﬁed
ersion of iNJ661 [78]. The integrated model was  able to repro-
uce in vitro experimentally measured dose–response curves of
-nitropropionate, an inhibitor of the glyoxylate shunt and the
ethylcitrate cycle.
Simulating single or double gene knock out mutants to dis-
over potential drug targets and synergistic combinations, greatly
epends on the network topology, the objective function, and the
ubstrate(s) available to the bacteria. The difference in speciﬁc
rowth rate predictions between the wild-type and simulated sin-
le or double knock out mutants, is mainly attributable to the rates
t which substrates are taken up and metabolites are secreted, and
ot to the compounds available. Synergistic combinations of drug
argets can also be found by gradually decreasing ﬂux through the
rst potential target, which can be found for example, through a
lassic gene essentiality approach, and afterwards identifying those
arts of the metabolism that are forced to carry a relatively higher
ux. Bhat and colleagues applied a similar strategy and studied
he effect of varying inhibition by isoniazid, a front-line drug, on
he metabolic state [12]. By gradually limiting the ﬂux through the
arget of isoniazid, InhA, they found that the ﬂux through various
athways was induced compared to the unperturbed state. These
athways could then potentially be analyzed to identify suitable
argets for drugs administered in combination with isoniazid.
These examples show the potential of using CB models to
ystematically probe the metabolic space of Mtb, generate novel
nsights and pin-point possible targets for interventions, with drugs
r otherwise.
.8. Combinatorial models and host drug targetsThe integrated human alveolar macrophage-Mtb model iAB-
MØ-1410-Mt661 combines the Mtb  metabolic model iNJ661 and
he ﬁrst reconstruction of human metabolism, Recon 1. Recently,munology 26 (2014) 610–622
the human model was  updated to the consensus reconstruction,
Recon 2 [79], which in turn can be combined with sMtb to cre-
ate an updated macrophage-Mtb model. It is crucial for such a
model to contain an accurate description of the phagosomal envi-
ronment and its contents, as this provides the framework for the
host–pathogen interaction and can have a large impact on the pre-
dictions of the metabolic state for both organisms. Although drug
target discovery is generally focused on the pathogen, there are also
opportunities to look at the host metabolism for drug targets. An
example of a host-targeted drug is thioridazine, which is postulated
to inhibit efﬂux of potassium and calcium from the phagolysosome
required for its acidiﬁcation [80]. The phagosomal environment
steers the pathogen metabolism, thus drugs targeting primarily
the host and altering this environment will result in metabolic
changes in Mtb  as well. This could result in a state that renders
the bacteria more susceptible to subsequent anti-TB drugs. A com-
bined model could provide additional host drug targets, however a
thorough understanding of the functioning and composition of the
phagosome is required. An experimentally validated and accurate
macrophage-Mtb model has much potential for drug target discov-
ery, especially for the identiﬁcation of synergistic drug targets, both
in the host and Mtb  itself or a combination of both.
5. Conclusions
The quality and predictive power of genome-scale recons-
tructions of the metabolism and transport of Mtb is gradually
increasing. Our current model, sMtb, outperforms considerably
previously published models in in vitro metabolic state predic-
tions (Table 4, Figs. 3 and 4) and speciﬁc growth rate predictions
(Table 3) as well as in vitro gene essentiality predictions (Table 2)
and drug–phenotype predictions (Table 5). However, there is still
ample room for improvement. The predictions of ﬂux through
the pentose phosphate pathway can be improved for all models,
while ﬂux through the glyoxylate shunt is still best predicted by
iNJ661. Better metabolic state predictions can be obtained through
an improved network topology, by improving the determination
of the biomass composition under different conditions, and by
deﬁning more accurately the objective function, as Schuetz and col-
leagues did [16] for a small E. coli model. Different combinations of
the growth related ATP coefﬁcient and the non-growth associated
maintenance also have an impact on the metabolic state predic-
tions, but these are hard to measure and their values can vary even
for well-known organisms [81,82]. Nevertheless they can be valu-
able parameters to ﬁt CB metabolic models to 13C data, thereby
improving their predictive power.
A CB metabolic model with sufﬁcient in vitro predictive power
forms the foundation for reliable in vivo metabolic state predic-
tions. Nevertheless, the in vivo metabolic state of Mtb  is arguably
not in steady state and relatively little is known about the ‘objective’
of Mtb  in the host. Efforts on both the experimental and model-
ing side of Mtb  metabolism continuous to shed light on its in vivo
metabolic state(s) and paves the way for the discovery of new (syn-
ergistic) drug targets and possible new intervention strategies. The
long term vision is that such a metabolic model will be one of the
modules of a larger multi-scale modeling framework that connects
a variety of models at different scales, each describing a partic-
ular subset of the behavior of Mtb  in infection settings. This will
thus ultimately contribute to the grander vision of a model-based
‘Virtual Patient’, with enormous potential to Health and Medicine.
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